These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 26040215)

  • 21. Efficacy and safety of methionine aminopeptidase 2 inhibition in type 2 diabetes: a randomised, placebo-controlled clinical trial.
    Proietto J; Malloy J; Zhuang D; Arya M; Cohen ND; de Looze FJ; Gilfillan C; Griffin P; Hall S; Nathow T; Oldfield GS; O'Neal DN; Roberts A; Stuckey BGA; Yue D; Taylor K; Kim D
    Diabetologia; 2018 Sep; 61(9):1918-1922. PubMed ID: 29992370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.
    Lau DC; Teoh H
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S134-41. PubMed ID: 26654857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current and emerging pharmacotherapies for obesity in Australia.
    Hocking S; Dear A; Cowley MA
    Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB; Aronne LJ
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medications for Obesity: A Review.
    Gudzune KA; Kushner RF
    JAMA; 2024 Aug; 332(7):571-584. PubMed ID: 39037780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Obesity Management in Adults: A Review.
    Elmaleh-Sachs A; Schwartz JL; Bramante CT; Nicklas JM; Gudzune KA; Jay M
    JAMA; 2023 Nov; 330(20):2000-2015. PubMed ID: 38015216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
    Khalil H; Ellwood L; Lord H; Fernandez R
    Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
    Verpeut JL; Bello NT
    Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug treatment of obesity: current status and future prospects.
    Kakkar AK; Dahiya N
    Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy for the management of obesity.
    Patel D
    Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
    Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
    Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
    Krentz AJ; Fujioka K; Hompesch M
    Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database.
    Firkins SA; Chittajallu V; Flora B; Yoo H; Simons-Linares R
    Obes Surg; 2024 May; 34(5):1415-1424. PubMed ID: 38512645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological treatment of non-responders following bariatric surgery.
    Vinciguerra F; Romeo LM; Frittitta L; Baratta R
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):196-204. PubMed ID: 33792233
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological management of obesity.
    Velazquez A; Apovian CM
    Minerva Endocrinol; 2018 Sep; 43(3):356-366. PubMed ID: 28462579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy for obesity in individuals with type 2 diabetes.
    Chukir T; Shukla AP; Saunders KH; Aronne LJ
    Expert Opin Pharmacother; 2018 Feb; 19(3):223-231. PubMed ID: 29376439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.